Suppr超能文献

放射化学疗法在肛管癌保守治疗中的应用:结果及放射剂量有效性的回顾性分析

Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.

作者信息

Ferrigno Robson, Nakamura Ricardo Akiyoshi, Dos Santos Novaes Paulo Eduardo Ribeiro, Pellizzon Antonio Cássio Assis, Maia Maria Aparecida Conte, Fogarolli Ricardo César, Salvajoli João Victor, Filho Waldec Jorge David, Lopes Ademar

机构信息

Department of Radiation Oncology, Hospital do Câncer A.C. Camargo, São Paulo, Brazil.

出版信息

Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1136-42. doi: 10.1016/j.ijrobp.2004.07.687.

Abstract

PURPOSE

This retrospective analysis reports the results on patients with anal canal carcinoma treated by combined radiotherapy and chemotherapy.

METHODS AND MATERIALS

Between March 1993 and December 2001, 43 patients with anal canal carcinoma were treated with radiochemotherapy at the Hospital do Cancer A.C. Camargo. Stage distribution was as follows: I, 3 (7%); II, 23 (53.5%); IIIA, 8 (18.6%); and IIIB, 9 (21%). The median age was 56 years (range, 36-77 years) with most patients being women (4:1). External radiotherapy (RT) was delivered at the whole pelvis followed by a boost at the primary tumor. The median dose of RT at the whole pelvis and at the primary tumor was 45 Gy and 55 Gy, respectively. Chemotherapy was carried out during the first and last 4 days of RT with continuous infusion of 5-fluorouracil (1000 mg/m(2)) and bolus mitomycin C (10 mg/m(2)). Median overall treatment time was 51 days (range, 30-129 days). Thirty-four patients (79%) did not receive elective RT at the inguinal region. Patient's age, tumor stage, overall treatment time, and RT dose at primary tumor were variables analyzed for survival and local control.

RESULTS

Median follow-up time was 42 months (range, 4-116 months). Overall survival and colostomy-free survival at 5 years was 68% and 52%, respectively. Overall survival according to clinical stage was as follows: I, 100%; II, 82%; IIIA, 73%; and IIIB, 18% (p = 0.0049). Complete response was observed in 40 patients (93%). Local recurrence occurred in 9 (21%) patients, and of these, 6 were rescued by surgery. Local control with a preserved sphincter was observed in 34 patients (79%). According to the RT dose, local control was higher among patients who received more than 50 Gy at primary tumor (86.5% vs. 34%, p = 0.012). Inguinal failure was observed in 5 patients (15%) who did not receive inguinal elective RT. Distant metastasis was observed in 11 patients (25.6%). Temporary interruption of the treatment as a result of acute toxicity was necessary in 12 patients (28%). Four patients developed mild chronic complications.

CONCLUSIONS

This analysis suggests that the treatment scheme employed was effective for anal sphincter preservation and local control; however, the incidence of distant metastases was relatively high. The clinical stage was the main prognostic factor for overall survival. Local control was higher in patients treated with doses of more than 50 Gy at primary tumor. The high incidence of inguinal failure implies the need for elective RT in this region.

摘要

目的

本回顾性分析报告了肛管癌患者接受放疗与化疗联合治疗的结果。

方法与材料

1993年3月至2001年12月期间,43例肛管癌患者在A.C.卡马戈癌症医院接受了放化疗。分期分布如下:I期,3例(7%);II期,23例(53.5%);IIIA期,8例(18.6%);IIIB期,9例(21%)。中位年龄为56岁(范围36 - 77岁),大多数患者为女性(4∶1)。全盆腔进行外照射放疗(RT),随后对原发肿瘤进行追加剂量照射。全盆腔和原发肿瘤的中位放疗剂量分别为45 Gy和55 Gy。化疗在放疗的第1天和最后4天进行,持续输注5-氟尿嘧啶(1000 mg/m²)并推注丝裂霉素C(10 mg/m²)。中位总治疗时间为51天(范围30 - 129天)。34例患者(79%)未接受腹股沟区的选择性放疗。分析患者年龄、肿瘤分期、总治疗时间以及原发肿瘤的放疗剂量等变量对生存和局部控制的影响。

结果

中位随访时间为42个月(范围4 - 116个月)。5年总生存率和无结肠造口生存率分别为68%和52%。根据临床分期的总生存率如下:I期,100%;II期,82%;IIIA期,73%;IIIB期,18%(p = 0.0049)。40例患者(93%)观察到完全缓解。9例(21%)患者出现局部复发,其中6例通过手术挽救。34例患者(79%)观察到保留括约肌的局部控制。根据放疗剂量,原发肿瘤接受超过50 Gy照射的患者局部控制率更高(86.5%对34%;p = 0.012)。5例未接受腹股沟区选择性放疗的患者(15%)出现腹股沟区失败。11例患者(25.6%)出现远处转移。12例患者(28%)因急性毒性反应而需要暂时中断治疗。4例患者出现轻度慢性并发症。

结论

本分析表明所采用的治疗方案对保留肛门括约肌及局部控制有效;然而,远处转移的发生率相对较高。临床分期是总生存的主要预后因素。原发肿瘤接受超过50 Gy剂量治疗的患者局部控制率更高。腹股沟区失败的高发生率意味着该区域需要进行选择性放疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验